Lung Cancer News and Research

Latest Lung Cancer News and Research

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Study shows end-of-life care varies widely

A new study released by the Dartmouth Atlas of Health Care finds that "America's hospitals treat patients with life-ending cancers very differently in their final months, with some deploying chemotherapy and other life-prolonging efforts until the end and others directing most of their patients into hospice," reports Kaiser Health News. The aggressive care may not be best for patients, and hospice may be a "more humane way to die," the report argues. A point the report doesn't address: that aggressive treatment "also adds to the drain on Medicare's pocketbook."

18 Nov 2010

Asbestos problem in NSW needs government attention: Report

A report from the NSW Ombudsman says that the state government is failing to deal with the deadly issue of asbestos despite repeated warnings regarding “immense” amounts of the dangerous material still scattered across NSW.

17 Nov 2010

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today that it will present new data at the inaugural CPRIT Innovations in Cancer Prevention and Research Conference, November 17-19, 2010 in Austin, TX.

17 Nov 2010

New OncoMap technique can detect point mutation in ovarian cancer

Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Today's Op-Eds: Congress needs conservative leadership; reviving tort reform; can states afford to drop Medicaid?

Nothing has gone quite so awry as the massive, government-run Obama health program, and it is plain that the individual mandate, the employee mandate, the abortion funding, the tangle of outsider/insider councils like the comparative effectiveness board and the effective nationalization of healthcare under grants of authority to the Department of Health and Human Services.

16 Nov 2010

Urgent need for bowel cancer screening funding

Bowel Cancer Foundation chairman, Graham Newstead feeling frustrated at the federal government’s indecision on bowel cancer screening funds has expressed his dismay. He suggested that the government should ensure the future funding for the screening test that has saved an estimated 11,000 lives since screening was introduced in 2006.

16 Nov 2010

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 International Pharmaceutical Federation Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition in New Orleans, La., Nov. 14-18.

16 Nov 2010

Graphic images of negative consequences of smoking have greatest impact on smokers

Marketing researchers at the University of Arkansas, Villanova University and Marquette University surveyed more than 500 U.S. and Canadian smokers and found that the highly graphic images of the negative consequences of smoking have the greatest impact on smokers' intentions to quit. The most graphic images, such as those showing severe mouth diseases, including disfigured, blackened and cancerous tissue, evoked fear about the consequences of smoking and thus influenced consumer intentions to quit.

15 Nov 2010

SuperGen to present three abstracts at EORTC-NCI-AACR International Symposium

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts detailing recent work with SuperGen compounds.

15 Nov 2010

Cerulean closes $24 million Series C financing by Lilly Ventures

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company has closed a $24 million Series C financing led by Lilly Ventures, with participation from all other existing investors including Polaris Venture Partners, Venrock, Lux Capital, and Bessemer Venture Partners.

15 Nov 2010

ICON, Proteome enter alliance to provide expanded biomarker solutions

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Proteome Sciences a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

15 Nov 2010

Women and cancer today

Experts have warned that women who have their breasts removed out of fear of a high hereditary risk of breast cancer may be doing so needlessly. Genetic tests like for the BRCA mutations have predicted a high risk of getting breast cancer in women with many breast cancer sufferers among their first degree relatives. Earlier studies suggest the risk of the mutation to predict the cancer 87% of the time. Now experts want that this is an overestimate.

11 Nov 2010

Dead litigant’s family bullied by tobacco company

In 2002 Jamie McCabe’s mother Rolah won a landmark legal battle against British American Tobacco and alleges that the family is still being harassed by the tobacco giant. Ms McCabe became the first Australian to successfully sue a tobacco company. She won $700,000 in compensation after Justice Geoffrey Eames, in the Victorian Supreme Court, found the tobacco company had destroyed potentially relevant documents about the damaging effects of smoking.

11 Nov 2010

USPTO issues Notice of Allowance to Asuragen’s mir-205 for lung cancer diagnosis

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today that it had received a Notice of Allowance from the United States Patent and Trademark Office for claims related to the use of mir-205 as a diagnostic in lung cancer.

11 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

Dana-Farber lends iPads to cancer patients to help them pass the time in clinic

Andrea Casella comes to Dana-Farber Cancer Institute every week for chemotherapy to treat her lung cancer. It's a full day. Recognizing that patients can spend hours in the clinic for treatment and tests, Dana-Farber has started lending iPads to patients like Casella to help them pass the time.

11 Nov 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Study shows end-of-life care varies widely

Asbestos problem in NSW needs government attention: Report

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

New OncoMap technique can detect point mutation in ovarian cancer

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Today's Op-Eds: Congress needs conservative leadership; reviving tort reform; can states afford to drop Medicaid?

Urgent need for bowel cancer screening funding

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

Graphic images of negative consequences of smoking have greatest impact on smokers

SuperGen to present three abstracts at EORTC-NCI-AACR International Symposium

Cerulean closes $24 million Series C financing by Lilly Ventures

ICON, Proteome enter alliance to provide expanded biomarker solutions

Women and cancer today

Dead litigant’s family bullied by tobacco company

USPTO issues Notice of Allowance to Asuragen’s mir-205 for lung cancer diagnosis

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Dana-Farber lends iPads to cancer patients to help them pass the time in clinic

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in